Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Trial of Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine and Cisplatin Compared to Gemcitabine and Cisplatin in Treatment-naïve Patients With Cholangio- and Gallbladder Carcinoma (IMMUCHEC)

Next Previous
Search
Trial Profile

A Randomized Phase II Trial of Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine and Cisplatin Compared to Gemcitabine and Cisplatin in Treatment-naïve Patients With Cholangio- and Gallbladder Carcinoma (IMMUCHEC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Cholangiocarcinoma; Gallbladder cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms IMMUCHEC

    • Most Recent Events

    • 13 Sep 2022 Results assessing the the efficacy of tremelimumab (two dosing regimens) in combination with CTx+D in treatment-naive patients with CHolangio- and gallbladdEr Carcinoma presented at the 47th European Society for Medical Oncology Congress
    • 01 Jun 2022 Status changed from active, no longer recruiting to completed.
    • 14 Oct 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top